Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Pharmacogenomics and Personalized MedicineOpen Access

Dual EGFR L858R and KRAS G12A Mutations in Lung Adenocarcinoma: A Rare Case Report and Literature Review

View Full Paper
Ask AI
Bookmark
Share

Authors

WGWei GuoJTJun TangHWHuaiwen Wang

Discussion

Loading...

Member takes

Overview

Case report shows dual EGFR L858R and KRAS G12A mutations in NSCLC, suggesting complex therapy needs.

Key Points

  • The patient presented with dual mutations of EGFR and KRAS, rare in lung adenocarcinoma.
  • Treatment with osimertinib and chemotherapy led to transient disease control but subsequent progression occurred.
  • Next-generation sequencing confirmed the presence of EGFR L858R and KRAS G12A mutations in the tumor.
  • The findings highlight the need for further research on treatment options for complex molecular profiles.

Cite This Study

Guo et al. (2025) studied this question.

synapsesocial.com/papers/68c1ce5d54b1d3bfb60f5282https://doi.org/10.2147/pgpm.s531038
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Primary collision lung adenocarcinoma harboring EGFR exon 21 L858R and KRAS G12C mutations: A Case Report2026
  2. 2Clinical course of non-small cell lung cancer with concurrent MET exon 14 skipping and KRAS G12C mutations treated with sequential targeted therapies: a case report2026
  3. 3Stage 4A Lung Adenocarcinoma with Rare EGFR Exon 21 L861Q and Exon 18 G719A Co-Mutations Showing Complete PET-CT Response to Osimertinib: A Case Report2026
  4. 4Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report2024 · 2 citations
  5. 5A Case Report of Concurrent Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719A) and Exon 21 (L833_V834delinsFL) Mutations and Treatment Challenges2024